WAYNE, Pa. and MISGAV, Israel, April 9, 2014 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE: MDGN ) (AIM:MEDU) (AIM:MEDG), the developer of Biopump (TM) a novel technology for the sustained production and delivery of therapeutic proteins in patients using ex-vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that all resolutions proposed at the Company's Annual Meeting of Stockholders held yesterday were duly passed.
Dr. Sol J. Barer, Dr. Eugene A. Bauer, Mr. Isaac Blech, Dr. Alastair Clemow, Mr. Michael F. Cola, Mr. Wilbur H. Gantz, Mr. Joseph J. Grano, Jr., Mr. Joel S. Kanter and Dr. Stephen D. McMurray were reelected to the Board of Directors. Dr. Andrew L. Pearlman retired from the Board of Directors at the meeting following the expiration of his term. "On behalf of the Board of Directors and the entire staff at Medgenics, I extend our deepest gratitude to Andy Pearlman for his over a decade of service to the company," said Sol J. Barer, Chairman of the Board of Medgenics.
Stockholders approved the cancellation of the Company's common stock shares from trading on the London Stock Exchange's Alternative Investment Market, or AIM. The last day of trading of the Company's common stock on AIM is expected to be April 15, 2014.
Stockholders also approved an amendment to the Company's Stock Incentive Plan, increasing the number of shares authorized to be issued under the plan by 2,000,000 shares.
Finally, stockholders ratified the appointment of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, to serve as the Company's independent registered public accounting firm for the year ended December 31, 2014.
Final voting tallies are subject to certification by the Company's inspector of elections and will be included in a Current Report on Form 8-K to be filed with the U.S. Securities and Exchange Commission within the next week.
About Medgenics
Medgenics is developing and commercializing Biopump™, a proprietary platform for the sustained production and delivery of therapeutic proteins using ex-vivo gene therapy and the patient's own tissue for the treatment of orphan and rare diseases. For more information, visit the Company's website at www.medgenics.com .
Forward-looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995, which include all statements other than statements of historical fact, including (without limitation) those regarding the Company's financial position, its development and business strategy, its product candidates and the plans and objectives of management for future operations. The Company intends that such forward-looking statements be subject to the safe harbors created by such laws. Forward-looking statements are sometimes identified by their use of the terms and phrases such as "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning, "expect," "believe," "will," "will likely," "should," "could," "would," "may" or the negative of such terms and other comparable terminology. All such forward-looking statements are based on current expectations and are subject to risks and uncertainties. Should any of these risks or uncertainties materialize, or should any of the Company's assumptions prove incorrect, actual results may differ materially from those included within these forward-looking statements. Accordingly, no undue reliance should be placed on these forward-looking statements, which speak only as of the date made. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, the events described in the forward-looking statements contained in this release may not occur.
Medgenics, Inc. John Leaman Stern Investor Relations Beth DelGiacco 212-362-1200 Abchurch Communications Harriet Rae / Joanne Shears/Jamie Hooper +44 207 398 7719 Oriel Securities (NOMAD & Broker) Jonathan Senior / Giles Balleny +44 207 710 7617
